The first-in-class drug – which targets CD20 and CD3 – is being assessed by the regulator for relapsed or refractory FL, the most common slow-growing form of non-Hodgkin lymphoma (NHL), after ...

The results of Phase III trials of the CD20-targeted human monoclonal antibody (mAb) ofatumumab in rheumatoid arthritis and non-Hodgkin's lymphoma (NHL) dampen hopes on the potential of the drug ...

The US regulator is reviewing odronextamab for two forms of B-cell non-Hodgkin lymphoma (NHL) – follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) – in patients previously ...

Lead programs include CD20-targeting CAR T cells for non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), being developed in collaboration with Fred Hutchinson Cancer Research Center ...

WASHINGTON, D.C.– All-time leading goal scorer Alex Ovechkin leads the top-seeded Washington Capitals against the Montreal Canadiens in the quarterfinals of the NHL Playoffs today – Monday ...